Activity
-
I've noticed a weird litigation trend lately in my neck of the woods. Recently, several different attorneys in western Pennsylvania have objected to…
I've noticed a weird litigation trend lately in my neck of the woods. Recently, several different attorneys in western Pennsylvania have objected to…
Liked by Marc Morris, MD JD
-
Avidity's CEO walked out of a $7.4 billion deal with Novartis. Cut off data room access. Started a capital raise instead. Moved on. Most boards…
Avidity's CEO walked out of a $7.4 billion deal with Novartis. Cut off data room access. Started a capital raise instead. Moved on. Most boards…
Liked by Marc Morris, MD JD
-
Working With Stars.... At some point in our careers, we will all have worked with remarkable individuals who will have a significant impact on our…
Working With Stars.... At some point in our careers, we will all have worked with remarkable individuals who will have a significant impact on our…
Liked by Marc Morris, MD JD
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
More activity by Marc
-
I’m excited to share that I’ve stepped into a new role as Chief of Staff to the EVP of Strategic Access, Policy & Communications at #Merck. At a…
I’m excited to share that I’ve stepped into a new role as Chief of Staff to the EVP of Strategic Access, Policy & Communications at #Merck. At a…
Liked by Marc Morris, MD JD
-
What better way to spend a Saturday morning than at your student's Terman Award ceremony? Huge congratulations to Héloïse Hoffmann on being…
What better way to spend a Saturday morning than at your student's Terman Award ceremony? Huge congratulations to Héloïse Hoffmann on being…
Liked by Marc Morris, MD JD
-
We’re excited to share that Gilead has exercised its option to license KT-200, our first-in-class, oral CDK2 molecular glue degrader, and advance the…
We’re excited to share that Gilead has exercised its option to license KT-200, our first-in-class, oral CDK2 molecular glue degrader, and advance the…
Liked by Marc Morris, MD JD
-
27 Years. 10 Modules. One "Monitoring Lens." 🔍 After nearly three decades in clinical research—navigating the complexities of the clinical research…
27 Years. 10 Modules. One "Monitoring Lens." 🔍 After nearly three decades in clinical research—navigating the complexities of the clinical research…
Liked by Marc Morris, MD JD
-
This week, we are thrilled to celebrate Prof Claire Harrison, recipient of the 2026 EHA Lifetime Achievement Award. Prof Harrison is honoured for…
This week, we are thrilled to celebrate Prof Claire Harrison, recipient of the 2026 EHA Lifetime Achievement Award. Prof Harrison is honoured for…
Liked by Marc Morris, MD JD
-
We are excited to share that Alexander Titus, Ph.D., our Vice President of AI and Data Science, has been honored with the Biocom California Life…
We are excited to share that Alexander Titus, Ph.D., our Vice President of AI and Data Science, has been honored with the Biocom California Life…
Liked by Marc Morris, MD JD
-
A FIRST AMENDMENT VICTORY! The Western District of Texas has enjoined enforcement of a Texas law that unconstitutionally compels speech by forcing…
A FIRST AMENDMENT VICTORY! The Western District of Texas has enjoined enforcement of a Texas law that unconstitutionally compels speech by forcing…
Liked by Marc Morris, MD JD
-
Following the exciting news of our oversubscribed $305 million Series F financing, our CEO Mathai Mammen, M.D., Ph.D., was interviewed by Kristen…
Following the exciting news of our oversubscribed $305 million Series F financing, our CEO Mathai Mammen, M.D., Ph.D., was interviewed by Kristen…
Liked by Marc Morris, MD JD
-
See how our integrated care and coverage removes prior authorizations and claims delays – so that when doctors recommend care, your employees get it.
See how our integrated care and coverage removes prior authorizations and claims delays – so that when doctors recommend care, your employees get it.
Liked by Marc Morris, MD JD
-
Sometimes I think Medical Affairs and Pharmacovigilance are the only teams in pharma that live in a constant paradox: PV: Spends 4 hours decoding a…
Sometimes I think Medical Affairs and Pharmacovigilance are the only teams in pharma that live in a constant paradox: PV: Spends 4 hours decoding a…
Liked by Marc Morris, MD JD
-
🚨 Novartis doubles down on RNA innovation. This week, Novartis announced a $12 billion acquisition of Avidity Biosciences, a US biotech pioneering…
🚨 Novartis doubles down on RNA innovation. This week, Novartis announced a $12 billion acquisition of Avidity Biosciences, a US biotech pioneering…
Liked by Marc Morris, MD JD
Other similar profiles
Explore more posts
-
Amgen
For people with high LDL (“bad”) cholesterol, lowering it plays a key role in cardiovascular health. Yet most patients at high risk for a heart attack or stroke are not reaching their LDL-C goals. At Amgen, we’re committed to advancing education and dialogue around earlier LDL-C assessment and proactive risk management. That’s why we’ve collaborated with healthcare leaders across the industry to share practical insights on why clinicians are central to improving LDL-C care. With earlier testing and management, we can help more patients take action sooner. Special thanks to Hilly Paige with Family Heart Foundation, Babak Abbaszadeh MD, MBA, Rigved Tadwalkar, MD, MS, FACC, FACP, C. Michael Gibson, M.S., M.D., for lending your voices to this important discussion. Learn more about advancing cardiovascular disease care: https://lnkd.in/eaGmG-MU
9 Comments -
Biotech Networks
LABN Trending News: Amgen to expand California headquarters with new $600M R&D center https://lnkd.in/gzhcfEPs Amgen will invest $600 million to expand its headquarters in Thousand Oaks, CA, bringing the industry’s total US manufacturing pledge to nearly $300 billion this year. The expansion will include a new research and development [...]
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content